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Inhibition of Platelet GPIba and Promotion of
Melanoma Metastasis
Luise Erpenbeck1,2, Bernhard Nieswandt1, Margarete Scho¨n1,2,3, Miroslava Pozgajova1 and
Michael P. Scho¨n1,2
Platelet glycoprotein Iba (GPIba) is part of the receptor complex GPIb-V–IX, which has a critical role in
hemostasis, especially through interactions with the subendothelial von Willebrand factor. As there is
accumulating evidence for a contribution of platelet receptors to hematogenous tumor metastasis, GPIba is an
interesting molecule to study in this context. We have investigated the effect of GPIba inhibition by monovalent
Fab fragments on experimental pulmonary metastasis in a syngeneic mouse model using C57BL/6 mice and
B16F10 melanoma cells. The early fate of green fluorescent protein (GFP)-transfected melanoma cells under
GPIba blockade was also assessed, as was the effect of GPIba inhibition on pulmonary metastasis in mice
lacking P-selectin. Surprisingly and, to our knowledge previously unreported, GPIba inhibition led to a
significant increase in pulmonary metastasis, and assessment of the early fate of circulating GFP-labeled B16F10
showed improved survival and pulmonary arrest of tumor cells shortly after GPIba inhibition, indicating that
inhibition of a platelet protein can, in some cases, promote metastasis of a malignant tumor. In contrast, GPIba
blockade in P-selectin-deficient mice had no enhancing effect on metastasis, suggesting the involvement of
GPIba in the initial, P-selectin-dependent steps of metastasis. These findings suggest that GPIba contributes to
the control of tumor metastasis, in addition to its role in hemostasis.
Journal of Investigative Dermatology (2010) 130, 576–586; doi:10.1038/jid.2009.278; published online 3 September 2009
INTRODUCTION
After early observations that depletion or reduction of
circulating platelets resulted in reduced experimental metas-
tasis formation of various tumors, the requirement of
(functional) platelets for successful hematogenous tumor
metastasis has been confirmed in many experimental settings.
In fact, it has been known for several decades that tumor cells
can induce platelet aggregation in vitro (tumor cell-induced
platelet aggregation, TCIPA) and that the capacity of different
tumor cell lines to produce this phenomenon may correspond
directly to their metastatic potential in vivo (Karpatkin et al.,
1988a, b). Hypotheses to explain the influence of platelets on
metastatic potential include the fact that platelets may shield
cancer cells from natural killer cell-mediated elimination
(Nieswandt et al., 1999; Palumbo et al., 2005), they con-
tribute to the interaction between tumor cells and the endothe-
lium, and they promote tumor cell growth by secreting cell
growth and angiogenesis factors (Kepner and Lipton, 1981;
Mohle et al., 1997; Nierodzik and Karpatkin, 2006). Further-
more, formation of tumor cell-platelet aggregates might
facilitate the arrest of tumor cells within the vascular system
(Kemp et al., 1971).
Several molecules essential for primary hemostasis and
blood coagulation, such as thrombin (Nierodzik et al., 1991),
fibrinogen (Biggerstaff et al., 1999; Palumbo et al., 2000), the
von Willebrand factor (vWF) (Terraube et al., 2007), tissue
factor, P-selectin (CD62P) (Romo et al., 1999; Chen and
Geng, 2006), and lysophosphatidic acid (Camerer et al.,
2004), are thought to contribute to the metastasis-promoting
activity of platelets on the basis of the observation that their
functional blockade or depletion resulted in impaired
experimental metastasis.
The platelet glycoprotein Ib (GPIb)-V–IX complex is one of
the major adhesive receptors constitutively expressed on the
plasma membrane of platelets. It is known to interact with
many important extracellular ligands such as vWF, coagulation
factors XI and XII, thrombospondin-1, high-molecular-weight
kininogen, as well as adhesion receptors P-selectin (CD62P)
and integrin Mac-1 (CD11b/CD18) (Andrews et al., 2003).
Interaction of the GPIb-V–IX complex with subendothelial vWF
at sites of vascular injury, especially under high flow
conditions, is essential for the initialization of primary
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hemostasis. In light of the importance of other platelet-related
factors for the metastatic potential of cancer cells, it was
reasonable to assume that this complex may participate in the
process of hematogenous metastasis. However, little is known
about the biological importance of the GPIb-V–IX complex,
aside from its role in hemostasis and thrombosis.
Recently, experimental evidence obtained using knockout
mice was reported, suggesting that the GPIba subunit of the
GPIb-IX–V complex may contribute to the processes control-
ling metastasis (Jain et al., 2007). The assessment of this
function of GPIba contains considerable challenges, as mice
lacking GPIba develop a murine equivalent of the human
Bernard–Soulier syndrome, which coincides not only with the
release of giant platelets but also with thrombocytopenia
(Nurden and Caen, 1975; Caen et al., 1976). However, no
such phenotype was observed when mice with a transgenic
expression of a variant GPIba subunit (IL-4R) or human GPIb
were used (Kanaji et al., 2002; Jain et al., 2007). To assess the
role of GPIba in metastasis and to test the antimetastatic
potential of GPIba inhibition directly, we used Fab fragments
of p0p/B, an mAb directed against the vWF-binding site on
GPIba (Bergmeier et al., 2000). As shown recently, treatment
with p0p/B Fab fragments has no effect on platelet counts, but
provides profound antithrombotic protection (Kleinschnitz
et al., 2007).
To investigate whether functional blockade of GPIba on
platelets had the same influence on tumor cell metastasis, as
was observed in GPIba knockout models, we used a
syngeneic model of pulmonary metastasis, in which we
injected C57BL/6 mice with B16F10 melanoma cells and
quantified the number of metastases that formed in the lungs.
Surprisingly, in this model, blockade of GPIba led to a
significant increase in metastasis. Thus, we can show that a
platelet adhesion receptor not only fails to promote meta-
stasis but also that its inhibition leads to an increased
metastatic potential of tumor cells, an observation that has, to
our knowledge, not been reported previously.
RESULTS
Murine platelets, endothelial cells, B16F10 melanoma cells, and
reactivity with the p0p/B (anti-GPIba) antibody
To ascertain that GPIba was expressed only on platelets,
and not on other cells relevant in our functional experi-
ments, thus extending a previous report (Bergmeier et al.,
2000), we first analyzed GPIba expression by flow
cytometry on isolated murine platelets in platelet-rich
plasma (PRP) and on B16F10 melanoma cells. (Figure 1a).
Although platelets clearly expressed GPIba, B16F10 mela-
noma cells showed no reactivity with p0p/B-FITC mAb.
Flow cytometry was also used to detect the minimal amount
of p0p/B Fab fragment necessary to achieve saturating
receptor binding in vivo. Given that 20mg of p0p/B Fab
fragments was sufficient to achieve receptor occupancy of
approximately 95% (Figure 1b), 50mg p0p/B Fab fragments
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Figure 1. Platelet glycoprotein Iba (GPIba) expression in lung tissue, platelets, and B16F10 melanoma cells. (a) Platelet-rich plasma (PRP) of 50ml or 106
melanoma cells suspended in 50ml phosphate-buffered saline (PBS) were stained with 0.5 mg of monovalent p0p/B (anti-GPIba)-FITC and analyzed by flow
cytometry. Mean fluorescence intensities of the stained cells are displayed in comparison with unstained platelets or melanoma cells (grey shaded histograms).
(b) Optimum antibody concentrations for complete receptor blockade were determined after injection of C57BL/6 mice with the amounts of monovalent p0p/B
(anti-GPIba) Fab fragments indicated on the X axis (n¼2 mice per group). Full blood of 50ml per mouse drawn from the retro-orbital plexus was diluted with
300ml heparin in PBS. Diluted blood of 50 ml was then incubated with 0.5 mg of p0p/B-FITC, and GPIba blockade was subsequently assessed by flow cytometry.
The graph shows the average receptor blockade in percent, ±SD. (c) Cryostat-cut lung sections of untreated C57BL/6 mice were stained immunohisto-
chemically using p0p/B- and p0p1-horseradish peroxidase-conjugated monoclonal antibodies directed against GPIba. Only intravascular platelets show
reactivity, whereas lung tissue is negative. Scale bar¼ 20mm.
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was used in all consecutive experiments to inhibit GPIba
in vivo.
As some reports have described the presence of GPIba on
cells of nonhematopoietic origin (Konkle et al., 1990;
Rajagopalan et al., 1992; Wu et al., 1997), we assessed
GPIba expression on endothelial cells and on other lung cells
by immunohistochemistry in lung sections of untreated
wild-type mice using two different horseradish peroxidase
(HRP)-conjugated antibodies (p0p/B and p0p1). Although
intravascular platelets could be readily visualized by immuno-
histochemical staining, no other cells within the lung sections
expressed GPIba (Figure 1c).
Blockade of GPIba and promotion of pulmonary melanoma
metastasis
The next series of experiments was designed to determine
whether a specific inhibition of GPIba, without induction of
thrombocytopenia, influences the metastatic potential of
melanoma cells. To verify the in vivo dependency of
melanoma metastasis on the presence of platelets in our
experimental system, we depleted platelets in C57BL/6 mice
using the monoclonal, divalent IgG antibody mix p0p3/p0p4
directed against the N-terminal 45-kDa portion of the GPIba
receptor, which induces a rapid and irreversible aggregate
formation and subsequent thrombocytopenia (Bergmeier
et al., 2000). As expected, a significantly reduced number
of pulmonary metastatic foci were formed when melanoma
cells were intravenously injected into platelet-deficient mice
as compared with the control C57BL/6 mice that received
only the isotype control (Figure 2a and b). The average
number of metastases in platelet-depleted mice was
17.9±9.3, whereas the average for the control lungs was
319.1±182.2 (n¼ 7 mice in both groups, Po0.001). To
demonstrate that metastasis can be impaired by blockade of
platelet receptors, a third group of control mice (n¼ 8)
received 100mg JON/A Fab fragments, an mAb directed
against GPIIb/IIIa (aIIbb3 integrin), known to be necessary for
metastasis in various tumor cell lines (Karpatkin et al.,
1988a, b). Yet another group of control mice (n¼8) received
100mg of rat IgG Fab fragments. Blockade of GPIIb/IIIa led to
significantly (P¼ 0.045) diminished metastasis, with an
average of 181.5±75.4 metastases per lung as compared
with the isotype control group with an average of
359.4±200.7 metastases per lung.
To investigate the role of platelet GPIba for the metastatic
potential of melanoma cells, we functionally inhibited
GPIba in C57BL/6 mice (n¼7) by injection of 50mg p0p/B
(anti-GPIba) Fab fragments 2 hours before tumor cell injec-
tion in our pulmonary metastasis model. Surprisingly, a
monovalent blockade of GPIba caused a strong and
statistically significant increase in metastasis in comparison
with control mice. The average number of metastases in the
p0p/B Fab group was 899.4±358.2 (P¼0.0047) (Figure 2c
and d). The surprising metastasis-promoting effect of GPIba
inhibition was confirmed in two independent additional
experiments (data not shown). In addition, histological
examination and objective computer-based morphometric
analysis of lung sections revealed a significant difference in
tumor masses per section in the three experimental groups
(Figure 2e and f). In the control group, the average sectional
area covered by tumor masses was 7.9±2.1% of the total
lung section. In the JON/A group (positive control), the
average value was 2.0±1.2% (Po0.001) as compared with
the isotype-matched negative control group. Starkly contrast-
ing, the average metastatic area in the p0p/B (anti-GPIba)
group was 17.3±6.3% (Po0.001 compared with that of the
control group).
Early effects of GPIba inhibition and melanoma metastasis
Given that the known biological functions of GPIba include
early phases of platelet aggregation and thrombus formation,
it seemed reasonable to assume that its inhibition in a tumor
model would primarily affect early steps during the initiation
phase of metastases, rather than later events such as growth
or local progression. To determine which phase of the
metastatic process was affected by GPIba blockade, C57BL/6
mice were injected with 50mg of inhibitory antibody p0p/B
Fab fragments or 50 mg of rat IgG Fab fragments at different
time points, either 2 hours before, together with, or 2 hours
after the injection of 2.5 105 B16F10 melanoma cells. The
quantification of pulmonary metastases 10 days later revealed
that blocking of GPIba functions was only effective when
performed during the very early phase of experimental
metastasis. Indeed, GPIba blockade 2 hours before tumor
cell inoculation or a simultaneous antibody/tumor cell injec-
tion led to significant increases in the average numbers of
metastatic foci compared with that of the isotype control
group, from 66.3±11.9 metastases/lung to 166.0±62 meta-
stases/lung (P¼ 0.044) and from 54.5±33.2 metastases/lung
to 194.0±61.7 metastases/lung, respectively (n¼4 mice in all
groups). In contrast, inhibition of GPIba 2 hours after tumor
cell injection did not have a significant effect compared with
the isotype control (P¼0.86, NS). Similar to the isotype con-
trol group (63.6±26.2 metastases/lung), the average number
of metastases in the p0p/B-treated group was 55.4±23.66
metastases/lung (P¼ 0.86; n¼ 5 mice in each group; Figure 3a).
To further elucidate the effect of GPIba inhibition on
melanoma metastasis during the first hours after tumor cell
transplantation in experimental pulmonary metastasis, we gen-
erated a B16F10 melanoma cell line stably transfected with
green fluorescent protein (GFP) to observe the early fate of
inoculated tumor cells under the influence of p0p/B Fab
fragments or of rat IgG Fab fragments. Given that the
transfected melanoma cells were subcloned to select for a
high expression of GFP, tumor cells could easily be visuali-
zed after transplantation into C57BL/6 mice. Injection of
50 mg Fab fragments was carried out 2 hours before intra-
venous injection of 2 106 GFP-expressing B16F10 melano-
ma cells. Mice were killed either without tumor cell injection
to control for autofluorescent structures, or 30minutes, 2hours,
or 5 hours after tumor cell injection. The numbers of GFP-
labeled tumor cells within the lungs were evaluated by two
complementary methods: microscopic quantitation of fluor-
escent cells in cryostat-cut lung sections (Figure 3b and c) and
flow cytometry of single-cell suspensions of lung tissue
(Figure 3d). At all three time points, the number of fluorescent
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B16F10 in lungs of injected mice was significantly higher in
the groups in which GPIba inhibition took place before tumor
cell injection as compared with the isotype control groups. As
early as 30minutes after tumor cell injection, 15.8±4.6
tumor cells were counted per microscopic field (10 lens) in
control lungs, whereas p0p/B treated-mice showed 18.6±4.3
tumor cells (P¼0.015, n¼3 mice per group, 13 microscopic
fields per sample). After 2 hours, an average of 10.6±3.3
tumor cells/field were detected in control lungs, whereas in
the lungs of mice in which GPIba had been blocked, the
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Figure 2. Targeting of platelet glycoprotein Iba (GPIba) and GPIIb/IIIa and pulmonary melanoma metastasis. (a) Pulmonary metastasis was assessed after
platelet depletion with 100 mg divalent p0p3/p0p4 anti-GPIb antibody mix intraperitoneally or injection of 100 mg control rat IgG antibody one day before
injection of 2.5 105 B16F10 melanoma cells through the lateral tail vein (n¼ 7 mice in both groups). Metastasis was analyzed 10 days after tumor cell
inoculation. Representative examples of lungs (two from each group) with metastatic foci are depicted. (b) The graph shows the average number of lung
metastases in each of the groups described in (a) (±SD, P-value is indicated). (c) C57BL/6 mice were injected with melanoma cells after blockade of
GPIba by 50 mg of monovalent p0p/B (left panels) or of GPIIb/IIIa by 100 mg of monovalent JON/A (middle panels) 2 hours before melanoma cell inoculation.
Control mice received 100mg of monovalent rat IgG 2hours before tumor cell injection (right panels). Lungs were removed 10 days after tumor cell injection,
and surface metastases were quantitated. The macroscopic pictures (two representative examples from each of the groups) show a clear reduction of metastasis
after blockade of GPIIb/IIIa, whereas inhibition of GPIba increased pulmonary metastasis. (d) Metastases per lung surface were counted in the groups described
in (c). The graph shows the average number of metastases in each group (n¼ 7 mice in the p0p/B group, n¼ 8 mice in both the control group and the JON/A
group, ±SD). P-values comparing the groups are shown. (e) Paraffin-embedded lungs of all mice were cut completely, stained with hematoxylin and eosin,
and examined histologically. Representative sections of four mice from each group are shown, arrows point to examples of metastatic foci in the lung sections.
Scale bar¼ 400mm. (f) Values in the graph represent the area covered by tumor mass relative to the total lung area as determined by objective computer-based
morphometric analysis (n¼ 7 mice in the p0p/B group, n¼ 8 mice in both the control and JON/A group, ±SD).
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Figure 3. Platelet glycoprotein Iba (GPIba) inhibition, pulmonary metastasis at different time points, and early fate of tumor cells under GPIba inhibition.
(a) Mice received either 50mg monovalent p0p/B (anti-GPIba) or 50mg of monovalent control rat IgG 2 hours before tumor cell injection, together with tumor
cells or 2 hours after tumor cell inoculation. B16F10 (2.5105) were intravenously applied per mouse. Quantitation of metastasis per lung surface was
performed 10 days afterward. Values shown in the graph depict the average numbers of pulmonary metastases (±SD, n¼ 4 mice in the first two groups, n¼ 5
mice in the last group). P-values comparing the groups are indicated. (b) B16F10 melanoma cells were stably transfected with green fluorescent protein (GFP).
Mice that had received either 50 mg of monovalent p0p/B (anti-GPIba) or 50 mg of monovalent rat IgG 2 hours earlier were injected with 2 106 GFP-expressing
B16F10 cells through the lateral tail vein. Control mice were injected with phosphate-buffered saline only. Mice were killed at different time points (30minutes,
2 hours, and 5 hours after melanoma cell injection). Representative sections (merged fluorescence and phase contrast images) from a control mouse
(left panel) and a mouse injected with 50 mg of p0p/B Fab fragments (right panel) are depicted. Scale bar¼10 mm. (c) The average number of GFP-labeled tumor
cells per microscopic field was determined in cryostat-cut lung sections from each group, as indicated using a fluorescence microscope (average±SD, n¼ 3
per group). P-values are indicated. (d) Single-cell suspensions were prepared from the lungs of control mice and from mice injected with GFP-expressing
melanoma cells as indicated. GFP-positive melanoma cells were quantitated by flow cytometry as a second independent method. Three independent
experiments were performed, and the results of each of these experiments are shown (labeled #1, #2, and #3).
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average number was 14.0±3.5 melanoma cells (Po0.001).
Finally, after 5 hours, 7.1±3.4 GFP-labeled melanoma cells/
field were detected in the lungs of mice that had received
isotype control mAbs, whereas the mice that had received
anti-GPIba showed an average of 10.1±4.3 melanoma cells/
field (P¼ 0.001).
Flow cytometric measurement of GFP-expressing cells in
single-cell suspensions of lung tissue yielded similar results.
Performing these types of experiments was technically
challenging, inasmuch as treatments at different time points
before tumor cell injections, preparations of single-cell sus-
pensions and analysis had to be performed in an exactly
timed manner within a single day. These constraints allowed
only a limited number of mice to be analyzed in one
experiment. As day-to-day variations in baseline metastasis
implantation had to be taken into account as well, we
analyzed one mouse a day for each condition (i.e., untreated
controls, 30minutes, 2 hours, and 5 hours after tumor cell
injection, each under isotype control conditions and GPIba
blockade and injected with the same batch of tumor cells).
The experiment was then repeated twice on two consecutive
days. Figure 3d depicts the results of all three experiments
showing consistently increased numbers of pulmonary
melanoma cells in GPIba-blocked mice.
Recruitment of Mac-1-positive cells into pulmonary tissue after
short-term metastasis
Given that the leukocyte-expressed receptor Mac-1 (CD11b/
CD18, aMb2 integrin) is also a binding partner of GPIba, we
tested the hypothesis that recruitment of Mac-1-positive
immune cells on tumor cell challenge was affected by GPIba
blockade. A marked pulmonary inflammatory response was
seen in mice injected with B16F10 tumor cells as early as
30minutes after inoculation. However, no differences were
apparent between the group that received p0p/B fragments
and the rat IgG control group. In both groups, recruitment of
Mac-1-positive cells subsided after 2 hours, and after 5 hours,
lung sections from both groups were comparable with those
of the control group that was injected with phosphate-
buffered saline (PBS) only (Figure S1).
Tumor cell-induced platelet aggregation under GPIba blockade
On the basis of previous findings suggesting that the ability of
TCIPA may be crucial for metastatic potential (Karpatkin
et al., 1988a, b; Nierodzik and Karpatkin, 2006), we tested in
another series of experiments whether a functional inhibition
of GPIba by p0p/B Fab fragments would lead to an alteration
of TCIPA in quantitative functional aggregometry assays. In
these experiments, PRP was incubated with either mono-
clonal, monovalent p0p/B or monoclonal, monovalent p0p1
antibody. The latter was used as control, because it recogni-
zes GPIba but does not interfere with its function. The speci-
fic inhibitor of ADP receptor P2Y12, AR-C69931MX, was
used as a positive control for the inhibition of aggregation, as
it is known that TCIPA is P2Y12 dependent (Alonso-Escolano
et al., 2004). As expected, incubation of PRP with B16F10
melanoma cells induced profound platelet aggregation
(Figure 4a). Although AR-C69931MX reduced TCIPA to
13% (±7.73%) as compared with TCIPA using B16F10
alone (n¼ 4 independent experiments in the B16F10 alone
group and n¼3 experiments in the AR-C69931MX group,
P¼0.00017), no reduction in TCIPA could be detected after
platelet incubation with either p0p/B or p0p1. Melanoma
cell-induced aggregation of p0p/B-incubated platelets was
96% (±13.07%; n¼4 experiments, P¼ 0.66 compared with
that of untreated controls), and aggregation of p0p1-
incubated platelets was 107% (±5.8%; n¼3 experiments,
P¼0.70 compared with that of untreated controls). Thus,
blocking GPIba did not affect TCIPA.
GPIba, P-selectin, and melanoma metastasis
Given that increased experimental tumor metastasis after
inhibition of a platelet surface receptor was a rather unusual
observation not seen with any of the other platelet antigens so
far, we next tested the hypothesis that the possibly protective
role of GPIba in experimental pulmonary metastasis is linked
to its interaction with P-selectin. P-selectin, a counterreceptor
for the GPIb-V–IX complex (Romo et al., 1999), mediates
cancer cell interactions with platelets and endothelial cells
(Kim et al., 1999; Borsig et al., 2001, 2002), and it has been
shown that lung metastasis after intravenous injection of
murine melanoma cells is severely reduced in P-selectin-
deficient mice (Ludwig et al., 2004). To test whether there
was a functional link between the interaction of P-selectin
with GPIba and the observed increase in metastatic foci after
GPIba inhibition, we inhibited GPIba with 50 mg of p0p/B
Fab fragments in wild-type and P-selectin-deficient C57/BL6
mice. The corresponding control mice of each genotype
received 50 mg of rat IgG Fab fragments. As expected,
P-selectin-deficient control mice showed overall reduced
metastasis compared with the wild-type group (Figure 4b).
Although in the wild-type group an increase in metastasis
from an average of 80.2±61.66 metastases per lung to an
average of 260.8±159.8 metastases per lung was induced by
injection of p0p/B (P¼0.046, n¼ 5 in both groups), no
increase in metastatic foci per lung could be achieved by this
treatment in P-selectin-deficient mice. In these knockout
mice, after treatment with p0p/B Fab fragments, the average
number of metastases was 38.5±5.8, whereas in the group
that received the isotype control Fab fragment, the average
number of metastases was 43.0±13.98 (P¼ 0.57, n¼4 in
both groups). Repetition of this experiment led to similar
results (data not shown).
Thus, a specific monovalent inhibition of platelet GPIba
without induction of thrombocytopenia led to markedly
increased melanoma metastasis, and this previously unre-
ported function was completely abrogated when a principal
counterreceptor of GPIba, P-selectin, was absent.
DISCUSSION
Our studies demonstrate the, to our knowledge previously
unreported, observation that monovalent inhibition of a major
adhesive platelet receptor, GPIba, increases the number of
B16F10 melanoma colonies, implying that, besides its well-
known role in hemostasis, GPIba is involved in the regulation
of tumor metastasis. Although a large number of molecules
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essential for blood coagulation and platelet function are
clearly linked to ‘‘successful’’ metastasis, this is an example
of a specific platelet receptor blockade in vivo that does not
diminish metastasis but increases the metastatic potential of
tumor cells.
Our results are in apparent contrast to previous studies in
knockout mice that either completely lacked GPIba or
expressed a variant GPIba subunit (IL-4R) (Kanaji et al.,
2002; Jain et al., 2007), as these experiments demonstrated
that GPIba deficiency is protective in experimental metastasis
(Jain et al., 2007). However, although knockout models
provide very important information, it must be considered
that a complete lack of GPIba induces profound thrombo-
cytopenia and morphological deviations in platelets. Even in
an ameliorated phenotype with a variant GPIba subunit,
alterations of platelet formation (Poujol et al., 2002) are very
hard to exclude. Using a monovalent antibody-based
approach, thrombocytopenia is not induced (Kleinschnitz
et al., 2007). In addition, knockout mice lack the proteoly-
tically shed extracellular domain of GPIba, termed glycocalicin,
in their plasma. It is known that high levels of glycocalicin are
present in the plasma of normal healthy humans and mice,
but its biological function is undefined. It cannot be excluded
that the reduction of metastasis in mice lacking functional
GPIba in their platelets is, at least in part, caused by the
lack of plasma glycocalicin. GPIba affected early phases
of experimental metastasis, such as the initial adhesion and
establishment of tumor cells, but not tumor growth itself.
This notion was corroborated by our time-course experi-
ments, in which the number of pulmonary metastatic foci
could only be increased when p0p/B Fab fragments were
applied either before or together with tumor cells. A similar
dynamic was reported after the inhibition of proteins impor-
tant for the primary arrest of tumor cells in the vasculature,
such as P-selectin (Ludwig et al., 2004). This observation is in
agreement with our data, showing that after a timespan of as
short as 30minutes, the arrest of GFP-labeled B16F10 cells in
the lungs was significantly more efficient in p0p/B-treated
mice than in the control groups.
As an approach to identify a possible mechanism under-
lying the metastasis-promoting effect of GPIba inhibition, we
investigated the influence of GPIba blockade on TCIPA, as
the ability of tumor cell lines to aggregate platelets in vitro
seems to correspond to their metastatic potential in vivo
(Karpatkin et al., 1988a, b). An alteration of this behavior,
possibly even an increase in TCIPA, would therefore have
been a conceivable mechanism to explain our observations.
However, no alteration of TCIPA was evident after platelet
incubation with p0p/B.
We also excluded a change in the recruitment of immune
cells as a possible cause for increased metastasis under GPIba
inhibition by p0p/B. Although we saw a marked recruitment
of Mac-1-expressing immune cells (e.g., macrophages and
granulocytes) in immunohistochemical stainings of lung
sections directly after tumor cell inoculation, the extent of
this inflammatory reaction was not dependent on whether the
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mice received p0p/B or control IgG previously. Thus,
blocking platelet GPIba did not affect the tumor cell-induced
rapid recruitment of cells of the innate immune system.
Finally, we focused on the role of P-selectin, an important
binding partner of the GPIb-V–IX complex. P-selectin, a
member of the selectin family of adhesion molecules, has
been demonstrated to mediate crucial cancer cell interactions
with platelets and endothelial cells, primarily through
sialylated fucosylated mucins expressed on circulating tumor
cells (Varki and Varki, 2002). P-selectin is stored within the
Weibel-Palade bodies of endothelial cells and in a-granules of
platelets, from where it can be rapidly translocated to the cell
surface upon activation of these cells to support adhesive
interactions. It has been shown that heparin can inhibit
P- and L-selectin and thus abrogate the prometastatic effect of
P-selectin (Borsig, 2007; Stevenson et al., 2007). However, the
role of P-selectin in the context of metastasis might go beyond
the mediation of cancer cell interactions to either platelets or
endothelial cells. Through its interaction with its platelet
counterreceptor, the GPIb-IX–V complex, P-selectin enables
platelets to roll on and adhere to activated endothelium.
Furthermore, the interface between P-selectin and GPIb-IX–V
could be important for the propagation of thrombus formation
by promoting interactions between activated platelets and
platelets that are as yet not activated (Romo et al., 1999),
accounting for the mild bleeding diathesis of P-selectin-
deficient mice (Subramaniam et al., 1996). It is conceivable
that both mechanisms have a role in blood-borne metastasis.
In our model of experimental metastasis, P-selectin-
deficient mice did not show increased metastasis after GPIba
blockade, pointing to an involvement of P-selectin in the
increase of metastasis observed after GPIba inhibition.
Considering this assumption and taking into account the
putative role of P-selectin interactions with GPIb-IX–V in
hemostasis, it is, at first glance, surprising that blockade of
this interaction would promote metastasis. However, we
have shown that blockade of GPIba does not interfere with
tumor cell-induced platelet aggregation, leading us to
propose the following hypothesis: a decrease in platelet
interactions with endothelial P-selectin could result in an
increased availability of P-selectin for direct cancer cell
interactions with the endothelium and, thus, a more
successful adhesion at the metastatic site. This hypothesis is
supported by the observation that, although platelet
P-selectin is important for tumor cell dissemination, en-
dothelial P-selectin contributes to the formation of metastasis.
In fact, B16F10 melanoma cells have been shown to roll on
endothelium in a P-selectin-dependent manner (Ludwig
et al., 2004). An enhancement of this function would offer
an explanation for the effects observed by us.
An alternative hypothesis to explain the effect seen after
GPIba blockade results from the observation that vWF
knockout mice present a very similar behavior in experi-
mental tumor metastasis (Terraube et al., 2007). As GPIba
interacts with vWF, mainly under conditions of high shear
(which might constitute considerable mechanical stress for
tumor cells), one could speculate that the abolishment of this
interaction would lead to an arrest of tumor cells in regions of
the vasculature in where mechanical conditions are more
favorable for tumor cell survival. However, whether there is a
connection between the phenotypes of vWF null mice and
mice that have received anti-GPIba needs yet to be investi-
gated to verify these assumptions. In our hands, vWF did not
induce tumor cell apoptosis (Figure S2).
In any case, our findings demonstrate that the roles
of platelet adhesion receptors can be very complex and
include important biological functions such as the regulation
of tumor cell metastasis. Over the past few years, tumor
therapies targeting blood-borne metastasis by inhibiting
several factors linked to platelet aggregation have been
discussed as an option for controlling malignant diseases and
for preventing the often fatal outcome associated with
hematogenous metastases. However, our current studies
show that targeting the GPIb-V–IX complex in cancer therapy,
as proposed by several groups, must be debated very care-
fully, especially in regimes that inhibit the vWF-binding site
on the receptor, as possibly the contrary effect of the desir-
able attenuation of the metastatic potential of tumor cells
could be produced by this treatment. It will be necessary to
further expand our knowledge on this subject by testing
GPIba inhibitors in different tumor cell lines and in comple-
mentary models of tumor cell metastasis to fully understand
the function of GPIba in the biological process of metastasis.
MATERIALS AND METHODS
Mice
Breeding pairs of C57Bl/6 as well as P-selectin-deficient (21) mice on
a C57Bl/6 genetic background (Charles River, Sulzfeld, Germany)
were kept in a specific pathogen-free environment on a 12 hours
light–dark cycle at the animal facility of the Rudolf Virchow Center.
Mice were between 6- and 9-weeks old when used for the
experiments, the groups were sex- and age-matched. The mice were
anesthetized by ether inhalation and killed by cervical dislocation
according to institutional guidelines. Mouse experiments were
approved by appropriate authorities (Regierung von Unterfranken).
Antibodies
A mixture of mAbs directed against mouse GPIba (p0p3 and p0p4),
known to induce rapid thrombocytopenia in vivo (Bergmeier et al.,
2000), as well as mAbs against mouse GPIIb/IIIa (JON/A) (Bergmeier
et al., 2002) and GPIba (p0p/B and p0p1) (Massberg et al., 2003),
was produced, characterized, and modified in our laboratories as
described. FITC-labeled p0p/B (50 mgml1), as well as HRP-labeled
p0p1 and HRP-labeled p0p/B, was also produced in our laboratories.
Fab fragments of monoclonal rat IgG (Sigma, Deisenhofen,
Germany) were prepared by enzymatic digestion and purified as
described (Nieswandt et al., 2000).
Cell culture conditions
B16F10 melanoma cells (Hart, 1979) were cultured in DMEM, high
glucose, with 10% fetal calf serum, 2mM L-glutamine, 100Uml1
penicillin, and 100mgml1 streptomycin (Gibco, Karlsruhe, Germany).
Flow cytometry
GPIba expression was assessed by flow cytometry using p0p/B mAb
conjugated to FITC (50 mgml1). B16F10 melanoma cells (1 106)
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in 50 ml PBS were stained with 0.5 mg p0p/B-FITC. For the generation
of PRP, mice were bled under ether anesthesia from the retro-orbital
plexus. Blood was collected in a tube containing 300 ml heparin
(Liquemin N25000, Roche, Basel, Switzerland), 20Uml1 in Tris-
buffered saline, and spun at 1,800 r.p.m. for 5minutes. The resulting
supernatant was again centrifuged at 900 r.p.m. for 6minutes. A
volume of 50 ml of PRP was incubated with 0.5 mg p0p/B (anti-
GPIba)-FITC and receptor expression was measured by flow
cytometry.
Assessment of receptor occupancy
The amount of p0p/B fragments necessary for optimal receptor
occupancy of GPIba in vivo was determined by injection of C57BL/6
mice with 5, 10, 20, 35, 50, or 100mg of p0p/B (anti-GPIba) Fab
fragments or with 100 mg control rat IgG Fab fragments (n¼ two mice
for each concentration). After 2 hours, mice were bled retro-
orbitally, and 50 ml of blood was collected in a tube containing
300ml heparin/TRIS (20Uml1). Diluted blood of 50ml was
incubated with 0.5 mg of p0p/B-FITC (50 mgml1 stock solution) for
10minutes at room temperature. Fluorescence produced by the
labeling of platelets with p0p/B-FITC was analyzed by flow cyto-
metry (FACScalibur, BD Falcon, Becton Drive Franklin Lakes, NJ).
As approximately 94.5% receptor blockade,±0.21% could already
be achieved at the concentration of 20 mg of Fab fragments per
mouse, 50 mg p0p/B of Fab fragments was used in all subsequent
experiments in vivo to inhibit GPIba. To test successful GPIba
blockade during lung metastasis experiments, approximately 50 ml of
blood was collected in a tube containing 2U of heparin (Roche)
after tumor cell injection. Again, receptor blockade was measured
by flow cytometry after staining of blood with p0p/B (anti
-GPIba)-FITC.
Immunohistochemistry
Horseradish peroxidase-labeled anti-GPIba mAbs (p0p1 and p0p/B)
were covalently labeled with HRP. The M1/70 clone was purchased
from ATCC, and anti-Mac-1 was produced and purified by affinity
chromatography in our laboratory. Cryostat-cut lung sections (5 mm)
were air-dried and fixed in acetone at 4 1C. Immunofluorescence and
immunohistochemical analysis using the avidin–biotin complex
method (Vector laboratories, Burlingame, CA) were performed as
previously described (Klein et al., 1990).
Experimental pulmonary metastasis
Subconfluent B16F10 cells were washed with PBS (Gibco), detached
using a 0.25% trypsin-0.02% EDTA solution (Sigma), washed in
DMEM containing 10% fetal calf serum, and resuspended in PBS.
Cells (2.5 105) in 150 ml PBS were injected per mouse through the
lateral tail vein. After 10 days, lungs were removed and rinsed with
PBS, lung weight was measured and the numbers of surface
metastases were counted. The right pulmonary lobes were conserved
in paraformaldehyde (4% in PBS) for paraffin embedding
and hematoxylin and eosin staining, and the left pulmonary lobes
were snap-frozen in liquid nitrogen for immunohistochemical
analyses.
To deplete platelets, the mice received 100mg of p0p3 and p0p4,
two monoclonal rat-anti-mouse antibodies directed against the
N-terminal 45-kDa portion of GPIba, in 200ml PBS or, as control,
100mg of monoclonal rat IgG in 200 ml PBS, both intraperitoneally,
1 day before injection of tumor cells. To inhibit GPIba, mice
received 50 mg of p0p/B Fab fragments retro-orbitally either 2 hours
before, concomitantly with, or 2 hours after intravenous tumor cell
inoculation. For blockade of GPIIb/IIIa, mice were injected retro-
orbitally with 100mg of JON/A (anti-GPIIb/IIIa) Fab fragments 2 hours
before tumor cell application. Control antibodies were either
monoclonal rat IgG or monoclonal rat IgG Fab fragments, as
appropriate, at respective concentrations.
Analysis of metastatic areas in lung sections
Hematoxylin and eosin staining of paraffin-embedded lung sections
was performed according to standard protocols. All microscopic pic-
tures were taken with a Zeiss Axioskop2 microscope (Jena, Germany)
and morphometric analyses were performed using the MetaMorph
(Molecular Devices, Downing town, PA) and Image J softwares (http://
rsbweb.nih.gov/ij/). Cross-sectional areas covered by tumor masses
were calculated in relation to the total cross-sectional surfaces.
Short-term metastasis experiments
B16F10 melanoma cells were stably transfected with GFP according
to an optimized protocol for B16F10 using 1.5 106 cells, 2 mg, and
100ml of Nucleofactor solution V (Amaxa, Cologne, Germany).
Transfected cells with a high expression of GFP were subcloned
thrice and cultured in DMEM (Gibco) containing 1mgml1 of the
G418 selection supplement (Sigma).
Age-, sex-, and weight-matched C57Bl/6 mice (6-weeks old),
which had received either 50 mg p0p/B Fab fragments or 50 mg rat
control Fab fragments 2 hours before tumor cell injection, were
injected retro-orbitally with 2 106 GFP-labeled melanoma cells in
150ml PBS or with PBS only as control. Mice that received tumor
cells were killed either 30minutes, 2 hours, or 5 hours after injection
(n¼ 3 mice per group). Control mice that received PBS only were
killed along with mice from the 30minutes group. The lungs were
excised and photographed. The right lung lobes were snap-frozen in
liquid nitrogen for histological analysis. From the left lung lobes, a
single-cell solution was prepared by incubation in liberase solution
(1mgml1 in serum-free DMEM, Sigma) for 90minutes at 37 1C. The
tissue was minced in Hank’s buffered salt solution containing 0.1%
BSA and passed through a 40 mm cell strainer (BD Falcon). The
suspension was washed once in Hank’s buffered salt solution (0.1%
BSA). For hypotonic lysis of erythrocytes, 2ml of ice-cold distilled
water, followed by 2ml of 0.8% NaCl solution, was added to the cell
pellet while vortexing. The cell solution was filled with Hank’s
buffered salt solution (0.1% BSA) and centrifuged for 5minutes at
1,600 r.p.m. Viable GFP-positive tumor cells were quantitated by
flow cytometry after propidium iodide staining, GFP-positive cells
were counted per 100,000 lung cells. In a complemetary analysis,
cryostat-cut sections of the right lung lobes were assessed microsco-
pically (Zeiss Axioskop). Phase contrast and fluorescence microscopy
allowed a topographic analysis of tumor cells within the lung tissue.
Aggregometry
Platelet-rich plasma was generated as described above. Platelets
were incubated with p0p/B or p0p1, a monoclonal, monovalent, yet
functionally not inhibiting or activating antibody directed against
GPIba (Bergmeier et al., 2000) at a concentration of 50 mgml1 each
or with the selective P2Y12 inhibitor, AR-C69931MX, at a final
concentration of 10 mM (gift from ASTRA Charnwood, Loughborough
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Leics, UK). Subconfluent B16F10 cells were washed with PBS
(Gibco), detached using a 0.25% trypsin-0.02% EDTA solution
(Sigma), washed in DMEM containing 10% fetal calf serum, and
resuspended in Tyrode’s buffer (137mM NaCl, 2mM KCl, 12mM
NaHCO3, 0.3mM NaH2PO4, 5.5mM glucose, 5mM HEPES, pH 7.3,
0.35% BSA) at 1 103 cells ml1. Aggregometry was performed in an
APACT 4 S Analyzer (Rolf Greiner BioChemica, Flacht, Germany)
with 110ml Tyrode’s buffer and 50ml of PRP. To induce aggregation,
50 ml of tumor cell suspension was added after 30 seconds.
Aggregation was monitored for 20minutes. Aggregation curves were
calculated as the percentage of average aggregation induced by
B16F10 alone. All experiments were performed at least thrice.
Statistical analysis
All statistical analyses were performed using Excel software
(Microsoft GmbH, Munich, Germany). Data are displayed as
mean±SD. P-values were determined using the two-tailed, two-
sided t-test. P-valueso0.05 were considered statistically significant.
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